NEW YORK (GenomeWeb News) – Circulating tumor cell-based diagnostics firm Epic Sciences today announced an agreement with Laboratory Corporation of America aimed at speeding up sample processing for Epic's technology in support of European clinical trials.

LabCorp's Central Laboratory in Mechelen, Belgium will process samples for Epic's clinical trial partners and customers as part of the deal. The samples will then be sent to Epic's laboratory in La Jolla, Calif. for downstream detection and molecular characterization of CTCs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.